ICH tackles inconsistent approaches towards evaluation of genotoxic impurities in drugs
This article was originally published in SRA
The International Conference on Harmonisation has issued guidance explaining how companies can address genotoxic impurities in pharmaceuticals to limit the potential carcinogenic risk of their products1,2.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.